根据FAERS数据库的真实世界数据进行了卢拉西的安全分析
Ziyi Luo1, Mengting Zhang1, Weijian Liang1
1Dongguan Key Laboratory of Stem Cell and Regenerative Tissue Engineering, The First Dongguan Affiliated Hospital, School of Basic Medical Sciences, Guangdong Medical University, Dongguan, China.
这项研究从现实数据中分析了卢拉西的不良事件 (AE),确定了已知的和新的安全问题,包括精神病,眼科和哺乳相关问题. 持续监测对于卢拉西的安全性至关重要.
科学领域:
- 药物监督 药物监督 药物监督
- 现实世界的证据.
- 药物安全 药物安全
背景情况:
- 评估卢拉西的现实安全概况.
- 分析营销后不良反应,以识别安全信号.
研究的目的:
- 通过使用现实世界的数据来评估卢拉西的安全性.
- 为了确定与卢拉西相关的已知和以前未报告的不良事件.
主要方法:
- 对FDA不良事件报告系统 (FAERS) 数据库的回顾性分析.
- 使用不成比例分析进行信号挖掘 (ROR,PRR,BCPNN,EBGM).
- 包括从2011年第一季度到2023年第四季度的数据.
主要成果:
- 从超过1000万份报告中,确定了12451个与卢拉西相关的不良事件 (AE).
- 发现与精神疾病,阿卡西西亚和帕金森休息有强烈的关联.
- 确定了新的眼部副作用和与哺乳相关的事件,这些事件以前没有在产品说明书中列出.
结论:
- 卢拉西与已知和意想不到的不良事件有关.
- 确定的安全问题包括眼部,哺乳相关和危及生命的事件.
- 强调需要对卢拉西进行持续的营销后监测.
更多相关视频
05:51Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Drug Regulation
Hazard Ratio
For example, in a clinical trial...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
